Axsome Therapeutics Inc experienced a notable decline in its stock price, dropping 4% in yesterday's trading session.
Axsome Therapeutics Inc (NASDAQ:AXSM) faced a setback yesterday, with its stock falling by 4%. This decline comes amidst a broader market environment where biotech stocks are under pressure due to macroeconomic factors.
Advertisement
Axsome Therapeutics Inc
AXSM.US
AXSM.US
Axsome Therapeutics Inc
WealthAwesomeMarket cap
$10.16B
52W high
$260.19
52W low
$117.30
1W change
-8.35%
Beta
0.71
Analyst Price Targets
Based on 19 analysts covering AXSM · as of Sep 28, 2026
Wall Street analysts forecast AXSM stock price to rise 53.2% over the next 12 months.
Consensus
Strong Buy4.74 / 5.00
Avg. Target
C$285.22
+53.2% Upside
Previously C$285.40 on Sep 25, 2026
Current Price
C$186.14
Last close
Analyst Breakdown (19 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AXSM's historical volatility
30-Day Vol
39.6%
Annualized
90-Day Vol
40.1%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$155.70
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$175.38 | C$152.96 – C$201.09 |
| 60 trading days | C$165.25 | C$136.18 – C$200.52 |
| 90 trading days | C$155.70 | C$122.86 – C$197.32 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should be cautious as Axsome's recent performance suggests potential volatility and uncertainty in the biotech sector, particularly with upcoming earnings reports.
4% Decline in Stock Price
Axsome's stock fell to a closing price reflecting investor concerns about its growth trajectory and market conditions.
Bull case
If Axsome can effectively capitalize on the growth of its AUVELITY product and navigate the tough market conditions, it may bounce back and offer significant upside potential.
Bear case
Ongoing pressure from macroeconomic factors and competition in the biotech space could further hinder Axsome's stock performance, especially if earnings do not meet expectations.
Market Overview
Advertisement
The biotech sector has been facing challenges recently, particularly after the Federal Reserve's recent interest rate hike. This has led to increased scrutiny on growth stocks, including Axsome Therapeutics, which has seen its year-to-date performance impacted significantly.
Analyst Insights
Despite the recent decline, analysts remain divided on Axsome's future. Some see potential in its AUVELITY product, which has shown promising prescription growth, while others caution that the stock's recent performance may indicate deeper issues that need addressing.
Looking Ahead
As Axsome prepares for its upcoming earnings report, investors will be closely monitoring its revenue projections and market strategies. The results could either reinforce confidence in the stock or lead to further declines if expectations are not met.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
